Sermorelin in Preclinical and Clinical Research: A Comparison with Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptides

Introduction Sermorelin (GRF 1-29) is a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It is used in laboratory research as a tool to interrogate the somatotropic axis, particularly growth hormone (GH) secretion from pituitary somatotrophs. This draft compares sermorelin with native GHRH, other GHRH analogs, and growth hormone-releasing peptides (GHRPs) in preclinical and clinical research contexts. It is intended for research-use-only discussion and does not provide clinical guidance.

Receptor Pharmacology Sermorelin binds the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed on pituitary somatotrophs. Native GHRH(1-44) and sermorelin share the same receptor; sermorelin represents a truncated form that retains the N-terminal region required for receptor activation. GHRPs, such as ghrelin mimetics, act primarily at the growth hormone secretagogue receptor (GHSR), a distinct receptor. Thus, sermorelin and GHRPs engage separate receptor systems, although both can stimulate GH release. This receptor-level distinction is a key comparison point in experimental design.

Pharmacokinetics and Stability Native GHRH is rapidly degraded in plasma, largely by dipeptidyl peptidase IV (DPP-IV), which cleaves at the N-terminus. Sermorelin is also subject to DPP-IV-mediated degradation, but its truncated sequence may alter degradation kinetics relative to full-length GHRH. GHRPs generally have different metabolic stability profiles and are not substrates for the same N-terminal cleavage. In research settings, these differences influence dosing intervals and sample handling.

Endocrine Effects in Research Models In animal and human studies, sermorelin has been shown to stimulate GH release in a dose-dependent manner. Because it acts at GHRHR, its effect is subject to negative feedback by somatostatin and insulin-like growth factor 1 (IGF-1). GHRPs can stimulate GH release through GHSR and may act synergistically with GHRH receptor agonists in some models. Comparative studies have examined whether combined GHRH-receptor and GHSR activation produces greater GH release than either alone. Such findings are model-dependent and should not be extrapolated to clinical use.

Comparison with Other GHRH Analogs Other GHRH analogs, such as CJC-1295 and tesamorelin, incorporate modifications intended to extend half-life or alter receptor interaction. Sermorelin lacks these modifications and is often used as a reference compound. In comparative research, differences in duration of action and magnitude of GH response are attributed to these structural modifications rather than to a different mechanism of action.

Limitations and Research Considerations Sermorelin is not approved for general clinical use in many jurisdictions, and its status varies. Research comparisons must account for species differences, assay sensitivity, and the pulsatile nature of GH secretion. Conclusions about relative efficacy should be confined to the specific experimental conditions. No claims about therapeutic benefit or dosing are made here.

Conclusion Sermorelin serves as a well-characterized GHRH receptor agonist for comparative studies of the somatotropic axis. Its distinct receptor target and pharmacokinetic profile differentiate it from GHRPs and from longer-acting GHRH analogs. Further research is needed to clarify context-dependent differences in GH release and downstream IGF-1 responses.